A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

• DOI: 10.1200/jco.2024.42.16_suppl.4512
• Publication Date: 2024-06-06T17:43:47Z
• Authors: Sahil D. Doshi; Nazli Dizman; Andrea Knezevic; Amina Touma; Reza Alaghehbandan; Yasser Ged; Moshe Chaim Ornstein; Andrew Warren Hahn; Pavlos Msaouel; Martin H Voss
• Keywords: Systemic therapy; Chromophobe cell

4512 Background: Chromophobe renal cell carcinoma (ChRCC) represents ~5-10% of all RCCs. Given its rarity, there is limited clinical trial data to guide systemic therapy for metastatic disease. Phase 2 trials have demonstrated that targeted agents inhibiting vascular endothelial growth factor receptor and mammalian target rapamycin similar efficacy in ChRCC compared conventional RCC. However, immune checkpoint inhibitor (IO) containing regimens appear less efficacious other RCC subtypes. Importantly, these efforts enrolled < 30 patients, larger scale studies are needed. Methods: We conducted a retrospective study patients with seen at 3 academic centers. Baseline characteristics treatment outcomes were obtained from EHR review. Patients categorized into 4 categories: 1) IO + doublets (e.g., lenvatinib plus pembrolizumab) 2) Pure monotherapy ipilimumab nivolumab) 3) everolimus) 4) sunitinib). calculated time failure (TTF) first-line overall survival (OS) by the Kaplan-Meier method. Median time-to-event was reported each category categories log-rank test. Results: Ninety-nine treated included; 62% male, 44% had sarcomatoid features, 33% IMDC favorable risk. Outcomes TTF OS summarized table below. 18-month rates 5 months 58% group, 15 80% IO/targeted doublet 17 65% 7 83% pure group. Treatment any agent yielded superior median (15 vs months, HR 0.48; 95% CI: 0.29, 0.80; p=0.005) (56 23 0.56; 0.30, 1.04; p=0.07). Most (64%) discontinued due progression; 25% toxicity. 11 ongoing analysis. Conclusions: In this observational analysis, higher those receiving monotherapies. continue build on dataset plan conduct progression free [Table: see text]